Medical Discovery NewsBridging the World of Medical Discovery and You

Recent Episodes

It's Revolutionary - A Cancer Vaccine

MP3 WAV

  • Immunotherapies are the best cancer fighting tools today, but they're expensive. They're customized to each patient, activating the person's immune system to kill cancer cells.

    Now there's an exciting alternative that's not only cheaper but may activate any person's immune system against cancer, a sort of universal cancer vaccine. Researchers have been injecting tumors with viruses and a variety of molecules in hopes of finding ones that would activate the body's immune system to kill cancer cells.

    Though they had found some that work in animals, none worked in humans until a group of scientists at Stanford decided to test twenty molecules they believed might work. They induced tumors in mice by injecting them just below the skin in two spots on the abdomen. Once the tumors started growing, they injected the twenty molecules alone or in combinations into one of the two tumors.

    They hit the jackpot with one pair of molecules. One is a small DNA molecule called a CpG and the other is an antibody called OX-forty. Both stimulate the immune system to enhance its cancer fighting activity. Alone, the two molecules had little effect on the tumors, but injected together, the injected tumors disappeared in under ten days. Even the uninjected tumors in the same animal disappeared within twenty days.

    Amazingly, eighty-seven of the ninety mice tested were cured of their cancers. Even in three mice where the cancer returned, the tumors regressed when they were re-injected. A clinical trial is already planned with fifteen cancer patients. How amazing if the trials work and a cancer vaccine becomes a reality.

More Information

Eradication of spontaneous malignancy by local immunotherapy
It has recently become apparent that the immune system can cure cancer. In some of these strategies, the antigen targets are preidentified and therapies are custom-made against these targets. In others, antibodies are used to remove the brakes of the immune system, allowing preexisting T cells to attack cancer cells. We have used another noncustomized approach called in situ vaccination...

Lymphoma
Lymphoma is a cancer that starts in cells that are part of the body's immune system. Knowing which type of lymphoma you have is important because it affects your treatment options and your outlook (prognosis). If you aren't sure which type you have, ask your doctor so you can get the right information...

TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
This phase I trial studies the side effects and best dose of the anti-OX40 antibody BMS-986178 when given together with the TLR9 agonist SD-101 and radiation therapy in treating patients with low-grade B-cell Non-Hodgkin lymphomas. TLR9 agonist SD-101 may stimulate the immune system in different ways and stop cancer cells from growing. Anti-OX40 antibody is a monoclonal antibody that enhances the activation of T cells, immune cells that are important for fighting tumors Radiation therapy uses high energy x-rays to kill cancer cells and may make them more easily detected by the immune system. Giving TLR9 agonist SD-101 together with anti-OX40 antibody BMS 986178 and radiation therapy may work better in treating patients with low-grade B-cell non-hodgkin lymphomas...

Two individuals wearing headphones stand in a recording booth, speaking into microphones with a music stand holding printed pages between them.

 Medicine...

Medicine is constantly advancing – that is a great thing about life in the 21st century. But it doesn’t just happen. Dedicated biomedical scientists are making discoveries that translate into those new medical advances.

Biomedical science is broad, encompassing everything from social science to microbiology, biochemistry, epidemiology, to structural biology and bioinformatics to name just a few areas. And, it can involve basic fundamental biology, the use of AI and chemistry to clinical studies that evaluate new medicines in patients.

No matter the research focus, the goal is always the same, to advance human health. It may take a few months, a few years or for fundamental science, a few decades. Few people make the connection that biomedical science is medicine and that biomedical scientists are working today on the medicine of tomorrow. Our weekly 500-word newspaper columns and 2-minute radio shows and podcasts provide insights into a broad range of biomedical science topics.

Medical Discovery News is dedicated to explaining discoveries in biomedical research and their promise for the future of medicine.

Podcasts

Alternatively, you can copy and paste the following web address (URL) into iTunes as a new subscription:
https://www.medicaldiscoverynews.com/shows/audio/mdnews.rss

You can also search and subscribe to "Medical Discovery News" in the podcast section of iTunes.

The www.medicaldiscoverynews.com web site and Medical Discovery News radio program (Program) are made possible by The University of Texas Medical Branch at Galveston (UTMB)as a community service and are intended to advance UTMB's mission of providing scholarly teaching, innovative scientific investigation, and state-of-the-art patient care in a learning environment to better the health of society and its commitment to the discovery of new innovative biomedical and health services knowledge leading to increasingly effective and accessible health care for the citizens of Texas.

All information provided on the web site and in the Program is for informational purposes only and is not intended for use as diagnosis or treatment of a health problem or as a substitute for consulting a licensed medical professional. Any information obtained by participating as a web site visitor or program listener is not intended to and should not be considered to constitute medical advice.

Thoughts and opinions expressed on the Program or on the website are those of the authors or guests and do not necessarily reflect the opinions of UTMB. The provision of links to other websites is not to be construed as written or implied sponsorship or endorsement of such websites by UTMB.

Please contact Dr. David Niesel or Dr. Norbert Herzog via email with any concerns, suggestions or comments.

All rights are reserved to information provided on the website or other information sources. No part of these programs can be reproduced stored in a retrieval system or transcribed in any form or by any means for personal or financial gained without the express written permission of Drs. Niesel and Dr. Herzog.